IRWDIronwood Pharmaceuticals, Inc.
Is the price fair?
Cheap against its own history. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Cheap vs its own history: P/E 5.0 vs a 11.4 median over 19 quarters (−56% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IRWD's price assumes
Ironwood Pharmaceuticals, Inc. trades at 5.01× earnings against 19.6× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.6 · cheaper than the typical name in its group
Details›
- Healthcare median P/E509 names
- 26.0
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.6
- Market capitalisation
- $635M
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 5.01× today against a 11.4× median |
| 52-week range | $1.43 – $5.39 |
| Today | $3.86 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #18 of 41 by RyuScore